Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
AssigneeSmithKline Beecham Corporation
InventorsRichard Mark Hindley, Stefan Roland Woroniecki
Life of this patent
Estimating the term…
Loading patent…
AssigneeSmithKline Beecham Corporation
InventorsRichard Mark Hindley, Stefan Roland Woroniecki
Estimating the term…
1 A process for preparing a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein: T represents a substituted or unsubstituted aryl group and T1 is O or S; which process comprises, treating a compound of formula (II), or a tautomeric form thereof and/or a salt thereof and/or a solvate thereof, wherein T and T1 are as defined in relation to formula (I), with a microbial reductase obtained from an appropriate red yeast; and thereafter, as required, preparing a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I) or a tautomeric form thereof; compounds prepared by such a process and the use of such compounds in medicine.
A process for preparing a compound of formula (I):
A process for the preparation of a compound of formula (I) (the ‘enantiomerically enriched compound (I)’) wherein greater than 50% w/w of said compound is in the form of a compound of formula (IA):
Enantiomerically enriched compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein greater than 50% w/w is in the form of compound (IA)
A compound of formula (IA) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in optically pure form.
Enantiomerically enriched compound (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.
Enantiomerically enriched compound (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular disease and certain eating disorders.
A pharmaceutical composition comprising enantiomerically enriched compound (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
Dependencies are inferred from the claim text.